ArticleScientific reports2016
A polyalanine peptide derived from polar fish with anti-infectious activities.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 55 citations in OpenAlex.
- Enhanced anticancer efficacy ofMaterials today. Bio · 2026Article
- Phage and endolysin-based inhibition ofFrontiers in cellular and infection microbiology · 2026Review
- A Critical Review of Quorum-Sensing Inhibition Strategies in Klebsiella Pneumoniae.Current microbiology · 2025Review
- Synergic Effect of the Antimicrobial Peptide ToAP2 and Fluconazole onInternational journal of molecular sciences · 2024Article
- Article
- Marine Antimicrobial Peptides: An Emerging Nightmare to the Life-Threatening Pathogens.Probiotics and antimicrobial proteins · 2024Review
- Innovative Biomedical and Technological Strategies for the Control of Bacterial Growth and Infections.Biomedicines · 2024Review
- Structure, Function, and Physicochemical Properties of Pore-forming Antimicrobial Peptides.Current pharmaceutical biotechnology · 2024Review
- Article
- Cloning, recombinant expression, purification, and functional characterization of AGAAN antibacterial peptide.3 Biotech · 2023Article
- Assessing the potential of the two-peptide lantibiotic lichenicidin as a new generation antimicrobial.World journal of microbiology & biotechnology · 2022Article
- EcDBS1R4, an Antimicrobial Peptide Effective againstInternational journal of molecular sciences · 2020Article
- Article
- Physicochemical-guided design of cathelicidin-derived peptides generates membrane active variants with therapeutic potential.Scientific reports · 2020Article
- Combating Antimicrobial Resistance With New-To-Nature Lanthipeptides Created by Genetic Code Expansion.Frontiers in microbiology · 2020Review
- Sarconesin II, a New Antimicrobial Peptide Isolated fromMolecules (Basel, Switzerland) · 2019Article
- Adevonin, a novel synthetic antimicrobial peptide designed from the Adenanthera pavonina trypsin inhibitor (ApTI) sequence.Pathogens and global health · 2018Article
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design.Nature communications · 2018Article
- Structure-function-guided exploration of the antimicrobial peptide polybia-CP identifies activity determinants and generates synthetic therapeutic candidates.Communications biology · 2018Article
- Comparative NanoUPLC-MSScientific reports · 2017Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 5 institutions in 4 countries.
Funding
Abstract
Due to the growing concern about antibiotic-resistant microbial infections, increasing support has been given to new drug discovery programs. A promising alternative to counter bacterial infections includes the antimicrobial peptides (AMPs), which have emerged as model molecules for rational design strategies. Here we focused on the study of Pa-MAP 1.9, a rationally designed AMP derived from the polar fish Pleuronectes americanus. Pa-MAP 1.9 was active against Gram-negative planktonic bacteria and biofilms, without being cytotoxic to mammalian cells. By using AFM, leakage assays, CD spectroscopy and in silico tools, we found that Pa-MAP 1.9 may be acting both on intracellular targets and on the bacterial surface, also being more efficient at interacting with anionic LUVs mimicking Gram-negative bacterial surface, where this peptide adopts α-helical conformations, than cholesterol-enriched LUVs mimicking mammalian cells. Thus, as bacteria present varied physiological features that favor antibiotic-resistance, Pa-MAP 1.9 could be a promising candidate in the development of tools against infections caused by pathogenic bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.